Roflumilast for asthma: Weighing the evidence.
Division of Pulmonology, Department of Medicine, University of Cape Town Lung Institute, Cape Town, South Africa. Electronic address: Eric.Bateman@uct.ac.za.
E D
ED
Bateman
Firestone Institute for Respiratory Health, Department of Medicine, McMaster University, Hamilton, Canada. Electronic address: obyrnep@mcmaster.ca.
P M
PM
O'Byrne
Pulmonary Department, Mainz University Hospital, Mainz, Germany. Electronic address: Roland.Buhl@unimedizin-mainz.de.
R
R
Buhl
LungClinic, Großhansdorf, Germany; Department of Medicine, Christian Albrecht University Kiel, Germany; Members of the German Center for Lung Research (DZL), Germany. Electronic address: k.f.rabe@lungenclinic.de.
K F
KF
Rabe
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000631:Aminopyridines / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D003521:Cyclopropanes / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D058988:Phosphodiesterase 4 Inhibitors / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D000631:Aminopyridines; D001549:Benzamides; D003521:Cyclopropanes; D058988:Phosphodiesterase 4 Inhibitors; C424423:Roflumilast
Asthma; FEV(1); ICS; Placebo; Roflumilast; Safety